Autolus Therapeutics plc Stock News

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced

Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call Transcript

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to announce Q4 earnings results on Thursday, Mar. 10, before market open.Consensus EPS estimate is -$0.36 and consensus revenue estimate…

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t

Autolus Therapeutics plc (NASDAQ:AUTL) shares, rose in value on Friday, 02/18/22, with the stock price down by -2.26% to the previous days close as strong demand from buyers drove the stock to $4.32. Actively observing the price movement in the last trading, the stock closed the session at $4.42, falling within a range of $4.32 Autolus Therapeutics plc (NASDAQ: AUTL) Stock Seems Like A Good Option Read More »

The heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreemen

Autolus Therapeutics plc - ADR (AUTL) shares closed today at 1.1% above its 52 week low of $4.60, giving the company a market cap of $339M. The stock is currently down 10.4% year-to-date, down 49.9% over the past 12 months, and down 81.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 42.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3892.5% The company's stock price performance over the past 12 months lags the peer average by 572.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 2,060,000 shares, a drop of 17.6% from the November 15th total of 2,500,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio []

Brokerages forecast that Autolus Therapeutics plc (NASDAQ:AUTL) will report sales of $270,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Autolus Therapeutics earnings. The lowest sales estimate is $240,000.00 and the highest is $300,000.00. Autolus Therapeutics posted sales of $400,000.00 during the same quarter last year, which would []

Brokerages predict that Autolus Therapeutics plc (NASDAQ:AUTL) will announce earnings per share (EPS) of ($0.40) for the current quarter, according to Zacks. Three analysts have issued estimates for Autolus Therapeutics earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.15). Autolus Therapeutics posted earnings per share of []

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,500,000 shares, an increase of 39.7% from the October 31st total of 1,790,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is [] The post Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update appeared first on ETF Daily News .

Marshall Wace LLP raised its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 200.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,749 shares of the companys stock after buying an additional 198,736 shares during the period. Marshall Wace LLPs holdings in Autolus []